CCNE1 and prostate carcinoma: Wang et al. found that PKMYT1 promotes the proliferation of prostate cancer by anchoring the expression of CCNB1 and CCNE1, and fostamatinib as an antagonist of PKMYT1 could energetically inhibited proliferation, suggesting that PKMYT1 may act as a potential curative target in prostate cancer [18].